Target intelligence / Profile preview

Polypeptide N-acetylgalactosaminyltransferase like 6 (GALNTL6)

Target: GALNTL6
Molecular classification: Enzyme, Glycosyltransferase, Polypeptide N-acetylgalactosaminyltransferase family

Overview

Polypeptide N-acetylgalactosaminyltransferase like 6 is a 601-amino-acid membrane-bound enzyme expressed mainly in human testis, brain, spinal cord, cerebellum, and skeletal muscle. It initiates O-glycosylation by transferring GalNAc from UDP-GalNAc to serine/threonine residues on specific proteins in the Golgi apparatus, a crucial step in modifying mucins and regulating protein function. This enzyme plays a key role in host-microbiota interactions by facilitating glycan digestion for commensal bacteria, thereby influencing immune modulation, nutrient digestion, pathogen colonization, and energy metabolism. Variants in the GALNTL6 gene (especially rs558129) have been associated with athletic performance traits, particularly in sprint and strength athletes. While its specific disease associations are limited, emerging evidence highlights its importance in metabolic and immune physiology.

Other names: Polypeptide N-acetylgalactosaminyltransferase-Like 6GalNAc-T6LUDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-Like 6GALNT17Putative polypeptide N-acetylgalactosaminyltransferase 17Protein-UDP acetylgalactosaminyltransferase 17

Mechanism of action

Not applicable due to lack of known drug interactions

Biological functions

Protein O-linked glycosylation (serine/threonine)Post-translational modificationRegulation of gut microbiome interactionEnergy metabolism regulationImmune system modulation

Disease associations

Inflammatory bowel diseaseWilliams-Beuren syndromePossible role in athletic performance phenotypes and metabolic health

Safety considerations

None documented; as a naturally occurring enzyme involved in glycosylation, no specific safety concerns are reported for its modulation or deficiency

Biomarkers

rs558129 polymorphism (C/T variants), studied as a biomarker for short-distance athlete performance and anaerobic metabolism

Beyond the preview

Go deeper on Polypeptide N-acetylgalactosaminyltransferase like 6 (GALNTL6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polypeptide N-acetylgalactosaminyltransferase like 6 (GALNTL6).

Explore the full profile